An observational study in Chronic Kidney Disease and Kidney Transplant, sponsored by Hospital del Mar. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Hospital del Mar · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Renal Insufficiency, Chronic with a site in Spain — 38 open to participants now, 55 under way, 23 of them phase 3. Renal Insufficiency, Chronic · Spain.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, this one is the 8th largest by planned enrollment of the 34 observational ones that give a count, is one of 15 that started in 2026, is one of 34 observational ones, reaches primary completion later than 17 of the 54 other live ones, and was the 165th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →38 of the 188 studies in Renal Insufficiency, Chronic with a site in Spain are open now. Recruiting first, the newest first:
Cardenal Herrera University · Sites in Spain
Ages 18–85
AstraZeneca · Sites in Spain, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Spain, United States, China and 5 more countries
Ages 2–18
Vifor Fresenius Medical Care Renal Pharma · Sites in Spain, China, Greece and 4 more countries
Ages 12–18
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 34 · Phase 3 80 · Phase 4 14
First in 1998; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 252 across the 154 interventional studies, 397 across the 34 observational. Of the 122 that completed or were terminated, 68 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 188 have an industry lead sponsor. The 10 most frequent:
Hospital del Mar is the lead sponsor of 45 studies on the registry; 17 are open to participants now.
Hospital del Mar has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
13 of the studies in Renal Insufficiency, Chronic with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction. Chronic kidney disease (CKD) affects 10%-15% of the global population and is projected to become the fifth leading cause of years of life lost by 2040. Despite the benefits of kidney transplantation (KT), access remains inequitable. In Spain, which leads the world in KT rates per million population, disparities may persist due to structural, territorial, and professional barriers. This study aims to explore the mechanisms underlying treatment deprivation and inequity in KT access using a mixed-methods approach.
Methods and analysis. A transformative mixed-methods design will be implemented in four phases: (1) systematic reviews on instruments assessing treatment deprivation and inequalities in CKD and KT; (2) a multicenter quantitative study and qualitative interviews with professionals and patients; (3) a pre-experimental evaluation of a training program on KT; and (4) triangulation and translation of findings to inform national policy. The protocol adheres to GRAMMS and PRISMA guidelines.
Ethics and dissemination. Approved by the Hospital del Mar Research Institute Ethics Committee (ID: XX), the study complies with EU data protection laws. Informed consent will be obtained. Findings will be disseminated via peer-reviewed publications, conferences, social media, and patient forums to support equity-focused strategies in KT.
METHODS AND ANALYSIS >> Study design The design of this research protocol follows the premises of the mixed-methods approach under the transformative paradigm 26,27. This means that various phases of data collection -both quantitative and qualitative- will be conducted, analyzed separately, and then integrated through methodological triangulation to corroborate and enrich the findings 28. The research will be centered on social justice, amplifying the voices of communities facing health inequalities or treatment deprivation. Using the transformative mixed-methods approach, different power structures that may be involved in the results will be analyzed and linked to actions that promote equity, ultimately providing a report with recommendations for action based on the results obtained 26,27. The achievement of results under this methodology and paradigm will be accomplished through various research phases, explained in detail below.
This protocol follows the Good Reporting of A Mixed Methods Study (GRAMMS) guidelines, recognized for ensuring high-quality evidence-based methodology 29.
Data collection and analysis Data collection and analysis will be carried out using a mixed approach, combining both quantitative and qualitative methods. This will result in four distinct research phases, tailored to the specific objectives of this research protocol.
Both reviews will be carried out following the methodological recommendations of the Joanna Briggs Institute (JBI) and will be reported according to the PRISMA 2020 guidelines 32,33. The protocols for the reviews will be registered in PROSPERO®. Searches will be conducted in the major electronic databases, using controlled vocabulary (MeSH) and will include peer-reviewed studies published between 2015 and 2025 in English, Spanish, French, or Portuguese. Eligibility criteria will be based on the PICOT framework, and include quantitative, qualitative, and mixed-methods research, as well as systematic and scoping reviews. Study selection, data extraction, and critical appraisal will be carried out independently by two or more reviewers, with discrepancies resolved by consensus or consultation with a third reviewer. Covidence® software will be used to manage the workflow.
Given the expected methodological heterogeneity, results will be synthesized narratively and organized thematically, according to the domains assessed, levels of analysis, validation approaches, and applicability of the instruments in both clinical and research contexts. These findings will provide a foundational knowledge base for the subsequent phases of the study.
> Phase 2. Inequities analysis This phase addresses objectives 3 and 4 by examining inequities in access to KT among individuals with CKD.
For the quantitative component (objective 3), a descriptive study will be conducted across Spain using a snowball sampling strategy through healthcare networks and patient organizations to ensure representativeness and inclusivity. Recruitment will continue until data saturation is reached, with a minimum of 500 participants to guarantee diversity across sociodemographic groups. Data will be collected through the questionnaires developed in Phase 1 (Appendix 1), complemented with sociodemographic and clinical variables to provide a comprehensive understanding of participants' health status and backgrounds. A multi-channel strategy will be applied to facilitate recruitment, involving healthcare professionals at nephrology and transplant centers, national and regional patient associations such as ALCER and ADER, and an online standardized interest form disseminated through institutional and collaborative networks, including ONT, SEDEN, and SEN. All participants will receive an information sheet and will be able to contact the research team directly to confirm their participation. No clinical information will be accessed without explicit consent, and contact details will only be shared if the participant initiates communication. This decentralized approach ensures voluntary participation and strict compliance with ethical standards in research involving potentially vulnerable populations. Statistical analysis will be carried out using SPSS® software. Descriptive statistics, including means, medians, standard deviations, and frequencies, will be used to summarize the sample characteristics, while inferential analyses such as t-tests, Wilcoxon tests, chi-square tests, and regression models will be applied depending on the type and distribution of the data. Assumptions for parametric tests will be verified, with non-parametric alternatives used when appropriate. Missing data will be managed through multiple imputation or complete-case analysis, depending on the extent and pattern of missingness, in order to ensure the robustness and validity of the findings.
For the qualitative component (objective 4), a descriptive study with a phenomenological orientation will be conducted to explore and understand in depth the experiences, perceptions, and meanings attributed to treatment deprivation by both healthcare professionals and individuals living with CKD. This approach will enable the identification of common patterns and differences between perspectives, providing a comprehensive view of the phenomenon from both sides of the healthcare relationship. Data will be collected through semi-structured, in-depth interviews guided by open-ended, non-directive questions designed to foster a fluid dialogue between interviewer and participant (Appendix 2). Two main groups of participants will be included: healthcare professionals involved in CKD care and KT, and patients with direct experience in the transplant process, including evaluation, waiting list, or transplantation. Healthcare professionals must have at least two years of experience in nephrology, transplant coordination, or related fields. Participants will be selected using purposive sampling with maximum variation to ensure diversity in roles, stages of CKD, and geographic regions. Interviews will be conducted by trained researchers or research assistants experienced in qualitative interviewing and working with vulnerable populations. Sessions will take place either in private spaces at participating healthcare centers (e.g., hospitals, transplant units, nursing schools) or through secure video calls, according to participants' preferences and availability, ensuring accessibility. Each interview is expected to last between 45 and 60 minutes, will be audio-recorded with prior consent, and subsequently transcribed verbatim for analysis. Follow-up interviews will be scheduled if necessary. Recruitment will continue until theoretical saturation is reached, defined as the point where no new themes or categories emerge from additional data 34. Data will be analyzed inductively using a thematic approach and content analysis to identify and categorize recurring patterns, with successive steps of coding, grouping into categories, and synthesizing into central themes. To ensure credibility and rigor, strategies such as investigator triangulation, participant validation, and reflective journaling of analytical decisions will be applied 35. All data will be anonymized using unique codes, stored securely, and handled in compliance with ethical standards. Atlas.ti software will be used to support the analytic process.
Upon completing this second research phase, we will have detailed data on inequities in access to KT in the Spanish context, together with the meanings attributed to this phenomenon by both the professional community and patients, providing comprehensive insights to inform the subsequent phases of the study.
> Phase 3. Impact of training In this third phase, objective 5 will be addressed by evaluating the impact of a training course in Spain on living donor KT for healthcare professionals. This particular course has been selected due to its established relevance within the Spanish context and potential impact upon access to KT: it has already completed three successful editions and has gained national recognition as one of the most important and well-regarded training programs on KT in Spain. Notably, the course is aimed at professionals working in non-transplant centers, particularly dialysis units and advanced CKD clinics, which positions it to directly influence early referral pathways and improve access to KT. Its consolidated presence and perceived influence on clinical practice make it a strategic candidate for evaluation.
A preexperimental quantitative study will be conducted with a pretest-posttest design. The study population will consist of healthcare professionals participating in the training, selected through convenience sampling. Data collection will be carried out through a structured questionnaire that will measure participants' knowledge, attitudes, and practices before, after, and one year after the course (Appendix 3). The questionnaire will include multiple-choice questions to assess knowledge, Likert scales to analyze attitudes, and questions about behaviors and clinical decision-making regarding living donor KT. The instrument's validity and reliability will be verified through prior piloting and consensus among the research team. Data analysis will involve descriptive statistics to characterize the sample and compare pre- and post-intervention results. Statistical tests such as the paired t-test or the Wilcoxon test, depending on the data distribution, will be applied to determine whether significant differences exist after training. Additionally, effect size measures, such as Cohen's d for continuous variables and Cramer's V for categorical variables, will be calculated to quantify the impact of the course on the evaluated variables.
The results obtained will help identify the effectiveness of the course in improving healthcare professionals' knowledge and perceptions about living donor KT, which can serve as the basis for future training strategies and for optimizing equitable access to KT within Spain.
> Phase 4. Integration of findings and contribution to the ATRAE national plan In the fourth and final phase of the project, the results obtained in the previous stages will be triangulated and synthesized to generate comprehensive, evidence-based knowledge (objective 6). This phase is conceived as an integrative component that will enable the transfer of research findings into actionable recommendations, directly contributing to the development of the national strategy for improving access to KT in Spain. The synthesis will support the creation of a consensus document within the ATRAE project: Optimizing Access to Kidney Transplantation in Spain. ATRAE is a national initiative led by the ONT, the Transplant Commission of the Interterritorial Council of the Spanish National Health System (CIT-SNS), and the Spanish Society of Nephrology (SEN), in collaboration with the Spanish Association of Urology (AEU), the Spanish Society of Nephrology Nursing (SEDEN), the Spanish Society of Immunology (SEI), and the Spanish Transplant Society (SET), and with the participation of the National Federation of Associations for the Fight Against Kidney Diseases (ALCER).
The research team will analyze and interpret the findings from both the quantitative and qualitative components, applying a triangulation process to enhance the validity and depth of interpretation. The results will be structured around key thematic areas such as regional disparities, evaluation and KT access processes, healthcare professional training, and the influence of social and structural determinants. Based on this synthesis, technical briefs will be prepared to highlight the most relevant insights, propose improvement strategies, and identify aspects that require further attention. These materials will be shared with the ATRAE working groups and coordination bodies, with the goal of supporting evidence-based decision-making and facilitating the integration of research findings into ongoing national planning processes.
Through this knowledge translation effort, the study positions itself as a relevant and timely contributor to the development of public policies, ensuring that its findings are not only scientifically rigorous but also transferable, actionable, and aligned with the institutional framework responsible for promoting equity in access to KT in Spain.
A transformative mixed-methods design will be implemented in four phases: (1) systematic reviews on instruments assessing treatment deprivation and inequalities in CKD and KT; (2) a multicenter quantitative study and qualitative interviews with professionals and patients; (3) a pre-experimental evaluation of a training program on KT; and (4) triangulation and translation of findings to inform national policy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention
Inequities in access to kidney transplantation among individuals with chronic kidney disease
Quantitative assessment of inequities in access to kidney transplantation using validated questionnaires developed in Phase 1, complemented by sociodemographic and clinical variables. The outcome will measure disparities according to age, sex, socioeconomic status, region, and clinical condition.
Time frame: Baseline (at study inclusion)
Patient experiences related to access to kidney transplantation
Analysis of experiences collected through structured questionnaires to evaluate patients' perceptions of their health status, quality of life, and barriers or facilitators in the transplant process.
Time frame: Baseline (at study inclusion)
Professional perspectives on inequities in access to kidney transplantation
Qualitative assessment through semi-structured interviews with nephrologists, nurses, healthcare managers, and patient advocates to explore their perceptions of systemic inequities and barriers in the transplant pathway.
Time frame: Within the first 12 months of the study
Thematic categories of inequities in kidney transplantation access
Inductive thematic analysis of qualitative data to identify key categories and central themes related to inequities in transplantation access, triangulated with quantitative findings.
Time frame: At study completion (24 months)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The following individual participant data (IPD) will be shared: de-identified sociodemographic variables (e.g., age, sex, region), clinical variables related to kidney disease stage and treatment modality, and responses to patient-reported outcome and experience measures (PROMs and PREMs) collected through standardized questionnaires. Data will be shared in aggregated and anonymized format to ensure confidentiality and will be used exclusively for research purposes in accordance with ethical approvals and participant consent.
Supporting information: Study protocol, Informed consent form
Time frame: Individual participant data (IPD) will become available after completion of the study and publication of the main results. Data will remain accessible for a period of 5 years following publication.
Access criteria: De-identified individual participant data will be made available to qualified researchers upon reasonable request. Access will require submission of a research proposal that aligns with the study objectives, approval by the principal investigator, and a signed data access agreement to ensure compliance with ethical and legal standards.
Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.
Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 11 months is below that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Hospital del Mar